These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
514 related articles for article (PubMed ID: 15698529)
1. Development of docetaxel in advanced non-small-cell lung cancer. Belani CP; Eckardt J Lung Cancer; 2004 Dec; 46 Suppl 2():S3-11. PubMed ID: 15698529 [TBL] [Abstract][Full Text] [Related]
2. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Edelman MJ; Clark JI; Chansky K; Albain K; Bhoopalam N; Weiss GR; Giguere JK; Kelly K; Crowley J; Gandara DR Clin Cancer Res; 2004 Aug; 10(15):5022-6. PubMed ID: 15297403 [TBL] [Abstract][Full Text] [Related]
3. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816 [TBL] [Abstract][Full Text] [Related]
4. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K; Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107 [TBL] [Abstract][Full Text] [Related]
5. Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Cappuzzo F; Rocha Lima CM; Sherman CA; Green MR Oncology (Williston Park); 2000 Jul; 14(7 Suppl 4):7-14. PubMed ID: 10960939 [TBL] [Abstract][Full Text] [Related]
6. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
7. Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. Pallis AG; Syrigos K; Kotsakis A; Karachaliou N; Polyzos A; Chandrinos V; Varthalitis I; Christophyllakis C; Ardavanis A; Vamvakas L; Vardakis N; Saridaki Z; Samonis G; Giassas S; Georgoulias V; Agelaki S Clin Lung Cancer; 2011 Mar; 12(2):100-5. PubMed ID: 21550556 [TBL] [Abstract][Full Text] [Related]
8. [Docetaxel and non-small cell lung cancer]. Le Guen Y; Le Cesne A Bull Cancer; 2004 Mar; 91(3):263-70. PubMed ID: 15171051 [TBL] [Abstract][Full Text] [Related]
9. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance. Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170 [TBL] [Abstract][Full Text] [Related]
10. Docetaxel in combination with platinums (cisplatin or carboplatin) in advanced and metastatic non-small cell lung cancer. Belani CP; Semin Oncol; 2002 Jun; 29(3 Suppl 12):4-9. PubMed ID: 12170445 [TBL] [Abstract][Full Text] [Related]
11. Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer. Bunn PA Semin Oncol; 1999 Feb; 26(1 Suppl 4):25-30. PubMed ID: 10201518 [TBL] [Abstract][Full Text] [Related]
12. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Chu Q; Vincent M; Logan D; Mackay JA; Evans WK; Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391 [TBL] [Abstract][Full Text] [Related]
13. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Pujol JL; Barlesi F; Daurès JP Lung Cancer; 2006 Mar; 51(3):335-45. PubMed ID: 16478643 [TBL] [Abstract][Full Text] [Related]
14. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group. Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802 [TBL] [Abstract][Full Text] [Related]
15. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan. Rigas JR Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410 [TBL] [Abstract][Full Text] [Related]
17. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial. Tas F; Demir C; Camlica H; Ustuner Z; Topuz E Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program. Ornstein DL; Nervi AM; Rigas JR Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137 [TBL] [Abstract][Full Text] [Related]
20. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]